Icatibant Hikma

Icatibant, the active ingredient in Icatibant Hikma, is a bradykinin B2 receptor antagonist presented as an injectable solution for intravenous use. It is used to treat acute attacks of hereditary angioedema in patients who experience sudden swelling.

GNH USA supplies Icatibant Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for the hereditary angioedema pathway, providing rapid relief of swelling during attacks.

- Hereditary angioedema type I: reduces swelling and associated pain. - Hereditary angioedema type II: alleviates edema and improves airway patency. - Hereditary angioedema with normal C1‑INH: controls acute symptom episodes.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: discomfort at the site of administration. - Redness or swelling at injection site: localized inflammatory response. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Flushing: temporary warmth and reddening of skin.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count. - Acute respiratory distress: difficulty breathing unrelated to swelling. - Cardiac arrhythmias: irregular heart rhythm.

When using Icatibant, clinicians should consider several safety measures.

- Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown excretion; weigh potential benefits against infant exposure. - Renal impairment: monitor patients with severe kidney dysfunction. - Concomitant ACE inhibitors: observe for additive bradykinin effects. - History of hypersensitivity: avoid if prior severe allergic reaction to the drug. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, heightening risk of angioedema. - Angiotensin receptor blockers (ARBs): similar risk of enhanced bradykinin activity.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure for additive hypotensive effect. - Antihistamines: may mask early signs of hypersensitivity. - Other B2 receptor antagonists: avoid concurrent use due to overlapping mechanisms.